Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.

Development 78

Development Drugs Manufacturing Immune Response 78

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Drug Discovery World

NOVEMBER 30, 2022

Associate Professor Keith Chappell, co-leader of UQ’s Rapid Response Vaccine Pipeline, said pre-clinical testing had shown the ‘Clamp2’ platform was meeting all expectations, producing stabilised antigens and inducing strong neutralising immune responses. “We Safeguarding against future pandemics .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

The Pharma Data

APRIL 15, 2022

Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike. The 50% neutralizing geometric mean titer (GMT) against Omicron was 993 (after three doses), compared to 27 after two doses.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

NOVEMBER 6, 2020

We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” Symvivo’s chief medical officer Eric Sievers said in a press release from the company. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

DECEMBER 20, 2021

The EUL from the WHO means that Novavax and its manufacturing partner Serum Institute of India (SII) can begin delivering the vaccine to the COVAX facility program, a global initiative headed by Gavi, the vaccine alliance, as a co-partner, which provides vaccines to low-income countries. Gavi secured 1.1

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

pharmaphorum

MAY 11, 2021

Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.

RNA 98

RNA Drugs Protein Immune Response 98

Cloudbyz

MARCH 6, 2024

This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

pharmaphorum

SEPTEMBER 30, 2020

The two antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

pharmaphorum

NOVEMBER 28, 2021

1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said they are poised to develop new shots if needed. Other vaccine manufacturers have also responded to the new variant. 1.1.529 version of its recombinant protein-based shot. — Sajid Javid (@sajidjavid) November 27, 2021.

Vaccination 111

Vaccination Vaccine Protein Genetics 111

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

pharmaphorum

AUGUST 11, 2021

The vaccine – based on a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike protein – is formulated with GlaxoSmithKline’s vaccine adjuvant, designed to boost the immune response.

Vaccination 98

Vaccination Vaccine Immune Response Trials 98

pharmaphorum

FEBRUARY 24, 2021

Changes in the “Spike” protein targeted by nearly all the vaccines approved or in development could also lead to more infectious variants, such as the strain that emerged in Kent and is now prevalent across most of the UK. If vaccines need updating, the FDA expects that manufacturing information will remain generally the same.

Vaccination 59

Vaccination Vaccine Immune Response Regulation 59

pharmaphorum

JULY 14, 2021

A few weeks ago, scientists in Germany said they had identified a possible mechanism behind the side effect related to the adenoviral vectors that both the AZ and J&J vaccines use to deliver the genetic code that stimulates the body to make the SARS-CoV-2 spike protein and stimulate an immune response.

Vaccination 116

Vaccination Vaccine Immune Response Protein 116

pharmaphorum

DECEMBER 22, 2020

There is no evidence to suggest the new strain causes more serious illness, but it does show variations in the “spike” protein that the virus uses to infect cells – the same protein that the Pfizer/BioNTech shot uses to confer immunity. The likelihood that our vaccine works … is relatively high.”.

Vaccination 81

Vaccination Vaccine Protein Immune Response 81

pharmaphorum

AUGUST 23, 2021

Ahmedabad-based Zydus Cadila has said it expects to launch ZyCoV-D in late September or early October, and expects to be able to manufacture around 100-120 million doses a year, with around 10 million available at launch. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

Pharmaceutical Technology

FEBRUARY 3, 2023

In Imbokodo, two parts of the immune response seemed to correlate with protection, one of which is the activity of antibodies to the V1 and V2 regions of the envelope protein, says Susan Zolla-Pazner, PhD, professor of medicine at the Icahn School of Medicine at Mount Sinai, New York City.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

SEPTEMBER 2, 2020

The vaccine candidate, developed in partnership by the firms, is based on the recombinant protein-based technology used in Sanofi’s seasonal influenza vaccines and GSK’s pandemic adjuvant technology. Sanofi and GSK are currently scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

JUNE 14, 2021

Novavax said last month it would have to delay the completion of filings in the US, UK and Europe, originally scheduled for this month, because there was still work to be done on the chemistry, manufacturing and controls (CMC) data that would be needed for an EUA. The UK has ordered 60 million doses of NVX-CoV2373 and a further 1.1

Vaccination 84

Vaccination Vaccine Immune Response Protein 84

pharmaphorum

MARCH 17, 2022

.” Both Pfizer’s BioNTech-partnered Comirnaty and Moderna’s SpikeVax vaccines use LNPs to carry mRNA coding for the SARS-CoV-2 spike protein. After dosing, the LNPs deliver the mRNA sequence into cells, which is then used by cellular machinery to manufacture the viral protein and stimulate an immune response.

Vaccination 52

Vaccination Vaccine Sales Immune Response 52

XTalks

AUGUST 14, 2023

XTALKS WEBINAR: Cancer Immunotherapy: Exploring Imaging as a Catalyst to Immune Response Prediction Live and On-Demand: Wednesday, September 27, 2023, at 2pm EDT (11am PDT) Register for this free webinar to discover the present and transformative impact of predictive biomarkers on immunotherapy response.

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

pharmaphorum

MAY 27, 2021

GSK and Sanofi think they could be on track for approval of the recombinant protein-based vaccine – delivered with GSK’s immune-response boosting adjuvant – before the end of the year. The phase 3 trial will include one shot targeting the original SARS-CoV-2 virus as well as a second against the B.1.351

Antibody 59

Antibody Immune Response Vaccination Vaccine 59

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

AUGUST 31, 2021

Like mRNA, it can be deployed to express proteins in the body – something that has been demonstrated clearly with Moderna and BioNTech’s COVID-19 vaccines for example – but Laronde reckons its platform can cover any protein type. The company has an ambitious goal of producing 100 eRNA medicines in the next decade.

RNA 52

RNA Protein Immune Response Medicine 52

pharmaphorum

NOVEMBER 25, 2022

A universal flu vaccine could help avoid the variability in effectiveness seen with current seasonal jabs, which is generally around 60%, but can fall to as low as 10% if health authorities and manufacturers incorrectly guess the strains that end up spreading in the flu season.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. With the commitment by our commercial partner, the Serum Institute of India, to manufacture at least 200 million doses annually in the coming years, the vaccine has the potential to have major public health impact if licensure is achieved.”.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

pharmaphorum

SEPTEMBER 15, 2020

The UK has also agreed to invest in Valneva’s manufacturing plant in Livingston, Scotland, to help scale up production of the vaccine, with the investment serving as a credit for future vaccine supply. The hope is that directly targeting the cells lining the airways may stimulate a more effective immune response against SARS-CoV-2.

Vaccination 80

Vaccination Vaccine Immune Response Manufacturing 80